Board

Prof. Dr. Erich Schlick, German national, born in 1952.

Dr. Schlick has over 25 years of experience in the healthcare sector. He spent five years at the US National Cancer Institute, and over 15 years with BASF Pharma, including ten years as the executive board member responsible for worldwide R&D. Dr. Schlick established BASF Pharma's immunology business, and its U.S. biotech centre specializing in immunology and monoclonal antibodies. From 2001 to September 2005, Dr. Schlick worked for 3i, where his last position was head of 3i's Healthcare Team in Germany and as Deputy Head of 3i Healthcare Worldwide. In September 2005, Dr. Schlick joined Wellington Partners as a General Partner of the Wellington Life Science Fund. Dr. Schlick is a qualified medical doctor and a professor of immune pharmacology at the University of Heidelberg. His other board memberships include Immatics (Germany), Sensimed (Switzerland), Symetis (Switzerland) and Zentralinstitut für Seelische Gesundheit, Mannheim, University of Heidelberg (University Center for Psychiatry). Dr. Schlick's past board memberships include the German companies Paion, Trigen, MBDsys and Elara.

Neil Goldsmith, British national, domiciled in Switzerland, born in 1963.

Neil Goldsmith co-founded Evolva SA and has been a member of the Board of Directors of Evolva SA and its Chief Executive Officer since April 2004.
Mr. Goldsmith has a 22 year track record in building successful biotech companies from the ground up. He was a co-founder of TopoTarget A/S and Personal Chemistry AB (now called Biotage AB), which are now listed on the Copenhagen and Stockholm exchanges, respectively. Prior to that, Mr. Goldsmith was CEO of Auda Pharmaceuticals (acquired by Phytera Inc.), GX Biosystems and PNA Diagnostics (acquired by Boehringer Mannheim). Previously he was VP Business Development for Pharmacia Biosensor (later BIAcore AB), and a Board Member of Quadrant Healthcare. Mr. Goldsmith started his career in biotech at Scientific Generics in Cambridge, UK after a short spell in consumer marketing. He received a First Class Honours BA Degree in Zoology from Balliol College, University of Oxford, and is a graduate of the New Enterprise Program at the Scottish Enterprise Foundation, University of Stirling.

Dr. André Lamotte, Swiss national, born in 1948.

Dr. André Lamotte has been a member of the Board of Directors since co-founding Arpida in 1997. He was Chairman of the Board of Directors until, 2009.
Dr. Lamotte is an entrepreneur who founded, co-founded or seed financed as well as led follow-up financing rounds for 18 pharmaceutical and biotech companies (Acambis-Oravax, Axovan, Creagen-Neurex, de Code genetics, Diatide, ICAgen, Inspire Pharmaceuticals, Paion, URRMA, Vernalis), medtech companies (Cryocath) and medical service companies (Laser Vision, Worldcare). He has been acting as a private entrepreneur and investor since 1996. Dr. Lamotte was also partner of NMT/HBM and the Harvard Medical School Venture Fund, general manager of Pasteur Merieux US operations and marketing manager at Sandoz. He has a PhD in chemical engineering from MIT, an MBA from Harvard and is a graduate from Ecole Centrale Paris. Dr. Lamotte is a member of the Board of Directors of the following firms: ICAgen and URRMA.

Dr. Jacques Mallet, French national, born in 1960.

Dr. Mallet started his career in 1989 as a Management Consultant for Andersen Consulting Paris, specialised in Healthcare and Pharmaceuticals. In 1996, he joined HMR/Aventis as Senior Director for Portfolio and Project Management based in Bridgewater (NJ, USA). In 2000, Dr. Mallet moved to the Monitor Group as Vice President, where he conducted a wide variety of strategy consulting engagements for the Life Sciences industry. Initially based in New York, he transferred to the Paris office in 2001. Dr. Mallet joined Auriga Partners in January 2006, where he is responsible for investments in the Life Sciences sector. Dr. Mallet is an MD from Paris University, was an intern at Assistance Publique / Hôpitaux de Paris, and also holds a BS from the American University in Paris. Dr. Mallet's other board memberships include: Alchimedics, Theraptosis and SuperSonic Imagine. Dr Mallet's previous board memberships include Tigenix and Implanet Partners.

Michel Pettigrew, MBA, Canadian national, domiciled in Switzerland, born in 1953.

Michel Pettigrew has been a member of the Board of Directors since 2007.
Mr. Pettigrew started his career in 1976 at Procter & Gamble Inc. in Canada, where he worked in various financial functions. In 1980, he joined the global pharmaceutical company Bristol-Myers Squibb, where he worked for units in Canada and the United States, as well as in Europe and Asia. Initially, his responsibilities were in Finance, but these rapidly grew to include full business accountability as General Manager of several subsidiaries in different parts of the world. In 2001, Mr. Pettigrew moved to Ferring Pharmaceuticals, a privately owned research-driven speciality biopharmaceutical company. He is currently President, Executive Board & Chief Operating Officer of Ferring Pharmaceuticals, overseeing all sales, marketing and manufacturing activities around the world. Mr. Pettigrew has a Bachelor of Commerce degree from McGill University in Montreal, Canada, and a MBA from York University in Toronto, Canada.

Ingelise Saunders, Danish national, born in 1949.

Ms. Saunders has more than 30 years of experience in the biotech/pharmaceutical industry. She is currently President and CEO of TD Vaccines A/S. Previously she was President and CEO of ACE BioSciences (DK) for five years. Prior to that, Ms. Saunders was CEO for three years of Celltech Pharmaceuticals plc (UK) with global commercial responsibility, and 16 years with Novo Nordisk in a number of top level executive management positions both in Denmark and in the UK. Ms. Saunders has a Cand.Pharm. degree from the University of Copenhagen, Royal Danish School of Pharmacy, and a Bachelor of Commerce degree in Marketing. Her other board memberships include: Scandinavian Life Science Invest AB, TopoTarget A/S, ALK-Abello A/S and Nordic Vaccine A/S (Chairman).

Jean-Philippe Tripet, CFA, Swiss national, born in 1963.

Mr. Tripet has over 15 years in healthcare venture experience. He is the Chairman and Managing Partner of Aravis Venture, a Swiss leading venture capital firm, which he founded in 2001. Previously, Mr. Tripet served as Senior Executive Vice President of Lombard Odier & Cie, where he headed Equity Asset Management and Research worldwide and also co-founded and headed the Lombard Odier Immunology Fund. Prior to that, he was Vice President of Equity Research at Union Bank of Switzerland, Zurich and London. Mr. Tripet received his Master in business administration from the University of Geneva. Mr. Tripet's other board memberships include: Omeros (USA), Merlion (Singapore), S Bio (Singapore), Symetis (Lausanne, Switzerland), Telormedix (Lugano, Switzerland), Synosia (Basel, Switzerland), and Fondation Fournier-Majoie pour l'Innovation (Belgium). He was previously a director of Combinature (Germany), Borean (Denmark), ESBATech (Switzerland) and Athelas (Switzerland).